Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure

Hepatology

Volumn 65, Issue 3, 2017, Pages 938-949

  Karvellas, Constantine J ^a   Speiser, Jaime L ^b   Tremblay, Mélanie ^c   Lee, William M ^d   Rose, Christopher F ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; FATTY ACID BINDING PROTEIN; HYPERTENSIVE FACTOR; LACTIC ACID; MANNITOL; PARACETAMOL; BIOLOGICAL MARKER; FABP1 PROTEIN, HUMAN;

ACUTE LIVER FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CLINICAL OUTCOME; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HUMAN; INTRACRANIAL HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; MULTIPLE ORGAN FAILURE; NEUROLOGICAL COMPLICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SEIZURE; SENSITIVITY AND SPECIFICITY; SURVIVAL; SURVIVOR; AREA UNDER THE CURVE; BLOOD; CAUSE OF DEATH; CHEMICALLY INDUCED; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; REGISTER; REPRODUCIBILITY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; SURVIVAL ANALYSIS;

ACETAMINOPHEN; ADULT; AREA UNDER CURVE; BIOMARKERS; CASE-CONTROL STUDIES; CAUSE OF DEATH; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; LIVER FAILURE, ACUTE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; REGISTRIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 85010789832     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28945     Document Type: Article

References (39)

1. O'Grady JG, Williams R. Classification of acute liver failure. Lancet 1993;342:743.
2. Fagan E, Wannan G. Reducing paracetamol overdoses. BMJ 1996;313:1417-1418.
3. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005;42:1364-1372.
4. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445.
5. Speiser JL, Lee WM, Karvellas CJ; US Acute Liver Failure Study Group. Predicting outcome on admission and post-admission for acetaminophen-induced acute liver failure using classification and regression tree models. PLoS One 2015;10:e0122929.
6. Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002;36:659-665.
7. Schmidt LE, Larsen FS. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007;45:789-796.
8. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002;359:558-563.
9. Koch DG, Tillman H, Durkalski V, Lee WM, Reuben A. Development of a model to predict transplant-free survival of patients with acute liver failure. Clin Gastroenterol Hepatol 2016;14:1199-1206.
10. Karvellas CJ, Safinia N, Auzinger G, Heaton N, Muiesan P, O'Grady J, et al. Medical and psychiatric outcomes for patients transplanted for acetaminophen-induced acute liver failure: a case–control study. Liver Int 2010;30:826-833.
11. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010;376:190-201.
12. Reddy KR, Schilsky M, Stravitz RT, Eberle C, Durkalski V, Fontana RJ, et al. Liver transplantation for acute liver failure: results from the NIH Acute Liver Failure Study Group. Hepatology 2012;56:246A.
13. Shakil AO, Kramer D, Mazariegos GV, Fung JJ, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl 2000;6:163-169.
14. Pelsers MM, Glatz JF. Detection of brain injury by fatty acid-binding proteins. Clin Chem Lab Med 2005;43:802-809.
15. Bass NM, Barker ME, Manning JA, Jones AL, Ockner RK. Acinar heterogeneity of fatty acid binding protein expression in the livers of male, female and clofibrate-treated rats. Hepatology 1989;9:12-21.
16. Pelsers M, Hermens W, Glatz JF. Fatty acid–binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005;352:15-35.
17. Pelsers MM, Namiot Z, Kisielewski W, Namiot A, Januszkiewicz M, Hermens WT, et al. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem 2003;36:529-535.
18. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-808.
19. Reuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz RT, et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann Intern Med 2016;164:724-732.
20. Conn HO, Lieberthal MM, eds. The Hepatic Coma Syndromes and Lactulose. Baltimore, MD: Williams & Wilkins; 1979.
21. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978;23:398-406.
22. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273-275.
23. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
24. Li X, Song X, Gray RH. Comparison of the missing-indicator method and conditional logistic regression in 1:m matched case-control studies with missing exposure values. Am J Epidemiol 2004;159:603-610.
25. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845.
26. Canty A, Ripley BD. Boot: Bootstrap R (S-Plus) Functions, 2012. http://CRAN.R-project.org/package=boot. R package version 1.3-4
27. van den Broek MA, Bloemen JG, Dello SA, van de Poll MC, Olde Damink SW, Dejong CH. Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgery. J Hepatol 2011;55:337-345.
28. Pelsers MM, Morovat A, Alexander GJ, Hermens WT, Trull AK, Glatz JF. Liver fatty acid–binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem 2002;48:2055-2057.
29. Akbal E, Koklu S, Kocak E, Cakal B, Gunes F, Basar O, et al. Liver fatty acid–binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection. Arch Med Res 2013;44:34-38.
30. Mikus M, Drobin K, Gry M, Bachmann J, Lindberg J, Yimer G, et al. Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. Liver Int 2016; doi: 10.1111/liv.13174.
31. Vergani L, Fanin M, Martinuzzi A, Galassi A, Appi A, Carrozzo R, et al. Liver fatty acid–binding protein in two cases of human lipid storage. Mol Cell Biochem 1990;98:225-230.
32. Negishi K, Noiri E, Doi K, Maeda-Mamiya R, Sugaya T, Portilla D, et al. Monitoring of urinary L-type fatty acid–binding protein predicts histological severity of acute kidney injury. Am J Pathol 2009;174:1154-1159.
33. Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014;60:622-632.
34. Bass NM. The cellular fatty acid binding proteins: aspects of structure, regulation, and function. Int Rev Cytol 1988;111:143-184.
35. Veerkamp JH, van Moerkerk HT. Fatty acid–binding protein and its relation to fatty acid oxidation. Mol Cell Biochem 1993;123:101-106.
36. Custer RP, Sorof S. Mitosis in hepatocytes is generally associated with elevated levels of the target polypeptide of a liver carcinogen. Differentiation 1985;30:176-181.
37. Wang G, Chen QM, Minuk GY, Gong Y, Burczynski FJ. Enhanced expression of cytosolic fatty acid binding protein and fatty acid uptake during liver regeneration in rats. Mol Cell Biochem 2004;262:41-49.
38. Donaldson BW, Gopinath R, Wanless IR, Phillips MJ, Cameron R, Roberts EA, et al. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. Hepatology 1993;18:1370-1376.
39. McPhail MJ, Farne H, Senvar N, Wendon JA, Bernal W. Ability of King's College Criteria and Model for End-Stage Liver Disease scores to predict mortality of patients with acute liver failure: a meta-analysis. Clin Gastroenterol Hepatol 2016;14:516-525.